Silence Therapeutics Files 8-K on Financials

Ticker: SLNCF · Form: 8-K · Filed: Feb 27, 2025 · CIK: 1479615

Silence Therapeutics PLC 8-K Filing Summary
FieldDetail
CompanySilence Therapeutics PLC (SLNCF)
Form Type8-K
Filed DateFeb 27, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, 8-k

TL;DR

Silence Therapeutics dropped an 8-K on Feb 27th covering financials and operations.

AI Summary

Silence Therapeutics plc filed an 8-K on February 27, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company is incorporated in England and Wales and its principal executive offices are located at 72 Hammersmith Road, London.

Why It Matters

This 8-K filing provides crucial updates on Silence Therapeutics' financial performance and operational status, which is important for investors to assess the company's health and future prospects.

Risk Assessment

Risk Level: low — This is a routine 8-K filing reporting financial information and does not appear to contain any significant new risks.

Key Players & Entities

  • Silence Therapeutics plc (company) — Registrant
  • February 27, 2025 (date) — Date of earliest event reported
  • England and Wales (jurisdiction) — State or other jurisdiction of incorporation
  • 72 Hammersmith Road, London (location) — Address of principal executive offices

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Silence Therapeutics plc's results of operations and financial condition, along with Regulation FD disclosures and financial statements and exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on February 27, 2025.

Where is Silence Therapeutics plc incorporated?

Silence Therapeutics plc is incorporated in England and Wales.

What is the address of Silence Therapeutics plc's principal executive offices?

The address of Silence Therapeutics plc's principal executive offices is 72 Hammersmith Road, London, W14 8TH, United Kingdom.

What is the company's telephone number?

The company's telephone number is +44 20 3457 6900.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on February 27, 2025 regarding Silence Therapeutics plc (SLNCF).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.